Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Spectral Signatures of L-DOPA-Induced Dyskinesia Depend on L-DOPA Dose and are Suppressed by Ketamine

View ORCID ProfileTony Ye, View ORCID ProfileMitchell J. Bartlett, Scott J. Sherman, View ORCID ProfileTorsten Falk, View ORCID ProfileStephen L. Cowen
doi: https://doi.org/10.1101/2020.07.14.202721
Tony Ye
1Department of Neurology, University of Arizona College of Medicine, Tucson, AZ, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tony Ye
Mitchell J. Bartlett
1Department of Neurology, University of Arizona College of Medicine, Tucson, AZ, United States
2Department of Pharmacology, University of Arizona College of Medicine, Tucson, AZ, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mitchell J. Bartlett
Scott J. Sherman
1Department of Neurology, University of Arizona College of Medicine, Tucson, AZ, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Torsten Falk
1Department of Neurology, University of Arizona College of Medicine, Tucson, AZ, United States
2Department of Pharmacology, University of Arizona College of Medicine, Tucson, AZ, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Torsten Falk
Stephen L. Cowen
3Department of Psychology, University of Arizona, Tucson, AZ, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephen L. Cowen
  • For correspondence: scowen@email.arizona.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

L-DOPA-induced dyskinesias (LID) are debilitating motor symptoms of dopamine-replacement therapy for Parkinson’s disease (PD) that emerge after years of L-DOPA treatment. While there is an abundance of research into the cellular and synaptic origins of LID, less is known about how LID impacts systems-level circuits and neural synchrony, how synchrony is affected by the dose and duration of L-DOPA exposure, or how potential novel treatments for LID, such as sub - anesthetic ketamine, alter this activity. Sub-anesthetic ketamine treatments have recently been shown to reduce LID, and ketamine is known to affect neural synchrony. To investigate these questions, we measured movement and local-field potential (LFP) activity from the motor cortex (M1) and the striatum of preclinical rodent models of PD and LID. In the first experiment, we investigated the effect of the LID priming procedures and L-DOPA dose on neural signatures of LID. Two common priming procedures were compared: a high-dose procedure that exposed unilateral 6-hydroxydopamine-lesioned rats to 12 mg/kg L-DOPA for 7 days, and a low-dose procedure that exposed rats to 7 mg/kg L-DOPA for 21 days. Consistent with reports from other groups, 12 mg/kg L-DOPA triggered LID and 80-Hz oscillations; however, these 80-Hz oscillations were not observed after 7 mg/kg administration despite clear evidence of LID, indicating that 80-Hz oscillations are not an exclusive signature of LID. We also found that weeks - long low-dose priming resulted in the emergence of non-oscillatory broadband gamma activity (> 30 Hz) in the striatum and theta-to-high-gamma cross-frequency coupling (CFC) in M1. In a second set of experiments, we investigated how ketamine exposure affects spectral signatures of low-dose L-DOPA priming. During each neural recording session, ketamine was delivered through 5 injections (20 mg/kg, i.p.) administered every 2 hours. We found that ketamine exposure suppressed striatal broadband gamma associated with LID but enhanced M1 broadband activity. We also found that M1 theta-to-high-gamma CFC associated with the LID on-state was suppressed by ketamine. These results suggest that ketamine’s therapeutic effects are region specific. Our findings also have clinical implications as we are the first to report novel oscillatory signatures of the common low-dose LID priming procedure that more closely models dopamine replacement therapy in individuals with PD. We also identify neural correlates of the anti-dyskinetic activity of sub-anesthetic ketamine treatment.

Competing Interest Statement

The authors have declared no competing interest.

Footnotes

  • tye{at}ucla.edu, mbartlet{at}email.arizona.edu, ssherman{at}neurology.arizona.edu, tfalk{at}arizona.edu, scowen{at}email.arizona.edu

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 19, 2020.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Spectral Signatures of L-DOPA-Induced Dyskinesia Depend on L-DOPA Dose and are Suppressed by Ketamine
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Spectral Signatures of L-DOPA-Induced Dyskinesia Depend on L-DOPA Dose and are Suppressed by Ketamine
Tony Ye, Mitchell J. Bartlett, Scott J. Sherman, Torsten Falk, Stephen L. Cowen
bioRxiv 2020.07.14.202721; doi: https://doi.org/10.1101/2020.07.14.202721
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Spectral Signatures of L-DOPA-Induced Dyskinesia Depend on L-DOPA Dose and are Suppressed by Ketamine
Tony Ye, Mitchell J. Bartlett, Scott J. Sherman, Torsten Falk, Stephen L. Cowen
bioRxiv 2020.07.14.202721; doi: https://doi.org/10.1101/2020.07.14.202721

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pathology
Subject Areas
All Articles
  • Animal Behavior and Cognition (2420)
  • Biochemistry (4779)
  • Bioengineering (3319)
  • Bioinformatics (14637)
  • Biophysics (6620)
  • Cancer Biology (5158)
  • Cell Biology (7405)
  • Clinical Trials (138)
  • Developmental Biology (4343)
  • Ecology (6864)
  • Epidemiology (2057)
  • Evolutionary Biology (9893)
  • Genetics (7331)
  • Genomics (9502)
  • Immunology (4540)
  • Microbiology (12644)
  • Molecular Biology (4928)
  • Neuroscience (28245)
  • Paleontology (199)
  • Pathology (803)
  • Pharmacology and Toxicology (1384)
  • Physiology (2014)
  • Plant Biology (4482)
  • Scientific Communication and Education (975)
  • Synthetic Biology (1295)
  • Systems Biology (3907)
  • Zoology (722)